Claims for Patent: 7,824,907

Summary for Patent: 7,824,907

Title:	Expression vectors comprising the mCMV IE2 promoter
Abstract:	The invention relates to an expression vector comprising the promoter of the mCMV-IE2 gene, or a functional expression promoting fragment thereof, and/or an enhancer of the mCMV-IE2 gene, or a functional expression enhancing fragment thereof, wherein expression vector does not contain any complete gene of the mCMV.
Inventor(s):	Chatellard; Philippe (Lausanne, CH), Imhof; Markus (Chexbres, CH)
Assignee:	Merck Serono SA (Coinsins, Vaud, CH)
Application Number:	10/548,364
Patent Claims:	1. An expression vector comprising SEQ ID NO: 1, wherein: (i) SEQ ID NO: 1 comprises a murine cytomegalovirus intermediate early 2 (mCMV-IE2) promoter; (ii) the expression vector does not contain any complete gene of the murine cytomegalovirus (mCMV); and (iii) said mCMV-IE2 promoter is operably linked to a DNA sequence coding for a polypeptide. 2. The vector according to claim 1, said vector comprising a first promoter comprising said mCMV-IE2 promoter and a second promoter that is different from said mCMV-IE2 promoter. 3. The vector according to claim 2, wherein the first and the second promoters are operably linked to DNA sequences coding for at least one polypeptide. 4. The vector according to claim 3, wherein the DNA sequences code for at least one protein of interest. 5. The vector according to claim 3, wherein the DNA sequences code for at least one marker protein. 6. The vector according to claim 3, wherein the DNA sequences code for at least one reporter protein. 7. The vector according to claim 2, wherein the first promoter and the second promoter are hi-directionally arranged. 8. The vector according to claim 2, further comprising one or more regulatory elements selected from the group consisting of 5'UTRs, introns, 3'UTRs, mRNA 3' end processing sequences, polyadenylation sites, and internal ribosome entry sequences (IRES). 9. The vector according to claim 8, wherein the regulatory element is an IRES, further comprising a DNA sequence coding for at least one polycistronic mRNA. 10. The vector according to claim 8, further comprising one or more DNA elements selected from the group consisting of insulators, boundary elements, locus control regions (LCRs), matrix attachment regions (MARs), and elements for recombination and cassette exchange. 11. The vector according to claim 3, wherein the DNA sequence coding for the polypeptide operably linked to the first promoter and the DNA sequence coding for the polypeptide operably linked to the second promoter code for the same polypeptide. 12. The vector according to claim 3, wherein the DNA sequence coding for the polypeptide operably linked to the first promoter and the DNA sequence coding for the polypeptide operably linked to the second promoter code for different polypeptides. 13. The vector according to claim 12, wherein the DNA sequence coding for the polypeptide operably linked to the first promoter codes for a first subunit of a dimeric or multimeric protein and the DNA sequence coding for the polypeptide operably linked to the second promoter codes for a second subunit of a dimeric or multimeric protein. 14. The vector according to claim 13, wherein one subunit is the alpha chain and the other subunit is the beta chain of a hormone selected from human follicle stimulating hormone (FSH), human leutropin-choriogonadotropic hormone (LH), human thyroid stimulating hormone (TSH), and human chorionic gonadotropin hormone (CG). 15. The vector according to claim 12, wherein one subunit is the heavy chain and the other subunit is the light chain of an immunoglobulin. 16. The vector according to claim 4, wherein the protein of interest is selected from the group consisting of follicle stimulating hormone (FSH), leutropin-choriogonadotropic hormone (LH), chorionic gonadotropin (CG), thyroid stimulating hormone (TSH), growth hormone, interferon, tumor necrosis factor (TNF) binding protein I, TNF binding protein II, a humanized anti-CD11 antibody, interleukin-18 binding protein (IL-18BP) and fusion proteins thereof. 17. The vector according to claim 5, wherein the marker protein is selected from the group consisting of adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo), dihydrofolate reductase (DHFR), hygromycin-B-phosphotransferase (HPH), thymidine kinase (tk), xanthine-guanine phosphoribosyltransferase (gpt), multiple drug resistance gene (MDR), ornithine decarboxylase (ODC) and N-(phosphonacetyl)-L-aspartate resistance (CAD), puromycin acetyltransferase (PAC), galactokinase, human folate receptor, and reduced folate carriers. 18. The vector according to claim 6, wherein the reporter protein is selected from the group consisting of luciferase, green fluorescent protein, alkaline phosphates, and horseradish peroxidase and combinations thereof. 19. The expression vector according to claim 1, wherein said mCMV-IE2 promoter is operably linked to a DNA sequence coding for a polypeptide selected from the group consisting of follicle stimulating hormone (FSH), leutropin-choriogonadotropic hormone(LH), chorionic gonadotropin (CG), thyroid stimulating hormone (TSH), growth hormone, interferon, tumor necrosis factor (TNF) binding protein I, TNF binding protein II, a humanized anti-CD11 antibody, interleukin-18 binding protein (IL-18BP), and fusion proteins thereof. 20. A host cell transfected with a vector according to claim 1. 21. The host cell according to claim 20, wherein the host cell is a CHO cell. 22. A process for the production of a polypeptide comprising culturing a host cell according to claim 20 under conditions allowing expression of the polypeptide. 23. The process according to claim 22, wherein the host cell is stably transfected. 24. The process according to claim 22, further comprising the step of isolating the polypeptide from the host cell or cell culture supernatant. 25. The process according to claim 22, further comprising the step of isolating the polypeptide from the host cell or cell culture supernatant. 26. The vector according to claim 16, wherein the protein of interest is IL-18BP or fusion proteins thereof. 27. The process according to claim 22, wherein said polypeptide is IL-18BP or fusion proteins thereof. 28. The expression vector according to claim 1, wherein said polypeptide is selected from the group consisting of interferon beta-1a, interferon beta-1b, an interferon receptor, an interleukin, erythropoietin, granulocyte colony stimulating factor, granulocyte-macrophage colony-stimulating factor, a pituitary peptide hormone, menopausal gonadotropin, an insulin-like growth factor, keratinocyte growth factor, glial cell line-derived neurotrophic factor, thrombomodulin, basic fibroblast growth factor, insulin, Factor VIII, somatropin, bone morphogenetic protein-2, platelet-derived growth factor, hirudin, epoietin, a recombinant LFA-3/IgG1 fusion protein, glucocerebrosidase and fusion proteins thereof.

Details for Patent 7,824,907

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974		2023-03-11
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984		2023-03-11
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985		2023-03-11